Logo Image
|Videos|January 3, 2017

Routine Testing for Powassan Virus

Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses routine testing for Powassan virus.

Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses routine testing for Powassan virus.

Interview Transcript (slightly modified for readability)

“At this point we wouldn’t recommend testing patients routinely for Powassan virus because we don’t know what clinical benefit that would have or how it would alter treatment. If you do have a patient [who’s] critically ill or a patient [who] has encephalitis and you live in an area endemic for Lyme, those patients should be tested for Powassan virus.”

Related to this article

View more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
ID Week Highlights Part 1
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Read more
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Read more